ArticleBMC cardiovascular disorders2026
Comparative evaluation of serum TGF-β1 and PDGF-BB levels across patients with normal coronary arteries, stable coronary artery disease, and acute coronary syndrome.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare serum levels of Transforming Growth Factor-Beta (TGF-β) and Platelet-Derived Growth Factor-BB (PDGF-BB) among patients with normal coronary arteries (NCA) and those with coronary artery disease (CAD) subclasses [stable CAD and acute coronary syndrome (ACS)], and to evaluate their potential diagnostic value and discriminatory power, particularly in identifying stable CAD.
methodsThis single-center, cross-sectional study included 176 patients who underwent coronary angiography. Participants were classified into normal coronary artery (NCA; symptomatic control), stable CAD, and ACS groups. Demographic, clinical, and biochemical data were recorded. Blood samples were collected for the analysis of TGF-β1 and PDGF-BB levels using ELISA kits.
resultsHypertension and diabetes mellitus were significantly more prevalent in the stable CAD group compared to others (p < 0.001). Both TGF-β and PDGF-BB levels were significantly elevated in patients with stable CAD compared to individuals with normal coronary arteries and those with ACS (p < 0.001). Multivariate regression analysis identified hypertension, diabetes, TGF-β, and PDGF-BB as independent predictors of stable CAD (p < 0.01 for all). ROC curve analysis demonstrated good diagnostic performance for TGF-β and PDGF-BB individually (AUC = 0.847, 0.798, respectively), with combined assessment further improving accuracy (AUC = 0.924).
conclusionSerum TGF-β and PDGF-BB levels are significantly increased in stable CAD patients relative to those with ACS and normal coronary anatomy. The combined evaluation of these biomarkers provides high diagnostic accuracy in distinguishing stable CAD, underscoring their potential role in the non-invasive assessment of chronic atherosclerotic disease. These findings support the use of TGF-β and PDGF-BB as complementary biomarkers for early identification and risk stratification in stable CAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.